Interleukin 6 Blockade for Hyperimmunoglobulin D and Periodic Fever Syndrome
- 1 March 2014
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in JCR: Journal of Clinical Rheumatology
- Vol. 20 (2), 103-105
- https://doi.org/10.1097/01.rhu.0000442576.41537.de
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Role of interleukin‐6 in a patient with tumor necrosis factor receptor–associated periodic syndrome: Assessment of outcomes following treatment with the anti–interleukin‐6 receptor monoclonal antibody tocilizumabArthritis & Rheumatism, 2011
- Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndromeRheumatology International, 2009
- Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatmentAnnals Of The Rheumatic Diseases, 2009
- Long-Term Follow-Up, Clinical Features, and Quality of Life in a Series of 103 Patients With Hyperimmunoglobulinemia D SyndromeMedicine, 2008
- Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-upClinical Rheumatology, 2008
- A patient with hyper-IgD syndrome responding to anti-TNF treatmentClinical Rheumatology, 2006
- Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome‐associated febrile crisisJournal of Inherited Metabolic Disease, 2006
- AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: A report of two casesArthritis & Rheumatism, 2006
- Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndromeNature Genetics, 1999
- Hyperimmunoglobulinemia D and Periodic Fever SyndromeMedicine, 1994